Mahendra A Patel

US Patent:

6458957, Oct 1, 2002

Filed:

Jul 12, 2000

Appl. No.:

09/614295

Inventors:

Anup K. Ray - Staten Island NY
Hiren Patel - Edison NJ
Shilpa V. Merai - North Brunswick NJ
Mahendra R. Patel - East Brunswick NJ

Assignee:

Geneva Pharmaceuticals, Inc. - Broomfield CO

International Classification:

C07D21126

US Classification:

546233, 546262, 546267, 546340, 564169, 544175, 544386, 544399

Abstract:

This disclosure relates to the use of ,-dibromo--chloroacetophenone compounds as intermediates for the preparation of aromatic carbonyl compounds, especially aromatic amides. The compound 2,5-bis(2,2,2-trifluoroethoxy)-,-dibromo--chloroacetophenone is especially useful as an intermediate for the preparation of flecainide, a known pharmaceutical.

US Patent:

6586598, Jul 1, 2003

Filed:

May 8, 2002

Appl. No.:

10/140638

Inventors:

Anup K. Ray - Staten Island NY
Hiren Patel - Edison NJ
Shilpa V. Merai - North Brunswick NJ
Mahendra R. Patel - East Brunswick NJ

Assignee:

Geneva Pharmaceuticals, Inc. - Broomfield CO

International Classification:

C07D21132

US Classification:

546220, 546233, 546337, 568308, 568309, 568335

Abstract:

This disclosure relates to the use of ,-dibromo--chloroacetophenone compounds as intermediates for the preparation of aromatic carbonyl compounds, especially aromatic amides. The compound 2,5-bis(2,2,2-trifluoroethoxy)-,-dibromo--chloroacetophenone is especially useful as an intermediate for the preparation of flecainide, a known pharmaceutical.

US Patent:

6693211, Feb 17, 2004

Filed:

Apr 28, 2003

Appl. No.:

10/424632

Inventors:

Durga Kumari - North Brunswick NJ
Mahendra R. Patel - East Brunswick NJ

Assignee:

Geneva Pharmaceuticals, Inc. - Broomfield CO

International Classification:

C07F 1502

US Classification:

556146, 556147, 424647, 514 53

Abstract:

This invention provides a process for preparing sodium ferric gluconate complex in sucrose using the following steps: a) combining a ferric salt solution with a weak alkali chosen from the group consisting of alkaline earth metal and ammonium salts, such as sodium carbonate, sodium bicarbonate, lithium carbonate, potassium carbonate, potassium bicarbonate, ammonium carbonate, ammonium bicarbonate and mixtures thereof, to form the ferric oxyhydroxide; b) combining ferric oxyhydroxide and sodium gluconate in solution to yield the sodium ferric gluconate complex; c) isolating the sodium ferric gluconate complex; and d) combining the sodium ferric gluconate with sucrose in solution to yield the desired sodium ferric gluconate complex in sucrose.

US Patent:

6962924, Nov 8, 2005

Filed:

Jul 17, 2003

Appl. No.:

10/621670

Inventors:

Anup Kumar Ray - Staten Island NY, US
Hiren Patel - Edison NJ, US
Mahendra R Patel - East Brunswick NJ, US

Assignee:

Sandoz AG - Basel

International Classification:

A61K031/4545
A61K031/445
C07D401/04
C07D401/08
A61P037/08

US Classification:

514290, 546 93

Abstract:

This invention provides a process of preparation of novel polymorphic hemifumarate salts of 8-chloro-6,11-dihyfro-11-(4-piperidylidene)-5H-benzo[5,6]-cyclohepta[1,2-b]pyridine, hereinafter called “desloratadine”. These polymorphic salt forms show much higher solubility in water and also in protic organic solvents compare to the parent desloratadine. The process of preparing the polymorphic forms comprising:.

US Patent:

7297789, Nov 20, 2007

Filed:

May 30, 2003

Appl. No.:

10/449643

Inventors:

Hiren V. Patel - Fords NJ, US
Anup K. Ray - Staten Island NY, US
Pramod B. Patel - Bordentown NJ, US
Mahendra R. Patel - East Brunswick NJ, US

Assignee:

Sandoz, Inc. - Princeton NJ

International Classification:

A61K 31/55
C07D 487/02
A61P 25/18

US Classification:

540557, 514220

Abstract:

A process for the preparation of polymorph Form I of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine, or olanzapine.

US Patent:

7727556, Jun 1, 2010

Filed:

May 6, 2005

Appl. No.:

11/124343

Inventors:

Gary Barbera - Medford NJ, US
Chetan Chhabildas Doshi - Plainsboro NJ, US
Mahendra R Patel - East Brunswick NJ, US
Pablo Davila - East Windsor NJ, US
Satishkumar Ambalal Patel - West Windsor NJ, US

Assignee:

Sandoz AG - Basel

International Classification:

A61K 9/14

US Classification:

424489

Abstract:

A pharmaceutical composition having improved solubility comprising a hydrophobic drug or pharmaceutically acceptable salt thereof and a compound having at least one carboxylic acid moiety, wherein the molar ratio of the compound having at least one carboxylic acid moiety to the hydrophobic drug or pharmaceutically acceptable salt thereof is from about 0. 1:1 to about 25:1. The pharmaceutical composition exhibits rapid dissolution upon contact with physiological solvents, such as water, saliva or gastrointestinal fluids.

US Patent:

7834176, Nov 16, 2010

Filed:

Jan 26, 2006

Appl. No.:

11/340284

Inventors:

Anup Kumar Ray - Staten Island NY, US
Hiren Kumar V. Patel - Fords NJ, US
Johannes Ludescher - Breitenbach, AT
Mahendra R. Patel - Milltown NJ, US

Assignee:

Sandoz AG - Basel

International Classification:

C07D 495/04

US Classification:

540557

Abstract:

The invention provides an Olanzapine pseudopolymoph Form E. The invention provides methods of preparing polymorphic Olanzapine Form E employing rapid crystallization and seeding. The invention provides methods of preparing anhydrous Olanzapine Form I from the Olanzapine Form E by step-wise drying.

US Patent:

7939104, May 10, 2011

Filed:

Feb 15, 2008

Appl. No.:

12/070071

Inventors:

Gary Barbera - Medford NJ, US
Chetan Chhabildas Doshi - Plainsboro NJ, US
Mahendra R Patel - East Brunswick NJ, US
Pablo Davila - East Windsor NJ, US
Satishkumar Ambalal Patel - West Windsor NJ, US

Assignee:

Sandoz AG - Basel

International Classification:

A61K 9/14
A61K 9/48
A61K 9/52

US Classification:

424489, 424451, 424452, 424457

Abstract:

A pharmaceutical composition having improved solubility comprising a hydrophobic drug or pharmaceutically acceptable salt thereof and a compound having at least one carboxylic acid moiety, wherein the molar ratio of the compound having at least one carboxylic acid moiety to the hydrophobic drug or pharmaceutically acceptable salt thereof is from about 0. 1:1 to about 25:1. The pharmaceutical composition exhibits rapid dissolution upon contact with physiological solvents, such as water, saliva or gastrointestinal fluids.